6.2.1.4 Summary of evidence and guidelines for the management of low-risk disease*,
Recommendations  Strength rating,
Watchful Waiting (WW),
Offer WW in asymptomatic patients with life expectancy < 10 years.  Strong,
Radical prostatectomy (RP),
Offer RP to patients with a life expectancy of > 10 years.   Strong,
Radical prostatectomy can be safely delayed for at least 3 months.   Weak,
Offer nerve-sparing surgery to patients with a low risk of extra-capsular disease on   Strong  that side.,
Radiotherapeutic treatment,
"Offer LDR brachytherapy boost combined with IMRT/VMAT plus IGRT to patients   with good urinary function and NCCN unfavourable intermediate-risk disease, in   combination with short-term ADT (4–6 months).",Weak
"Offer high-dose rate (HDR) brachytherapy boost combined with IMRT/VMAT plus   IGRT to patients with good urinary function and NCCN unfavourable intermediate-  risk disease, in combination with short-term ADT (4–6 months).",Weak
Other therapeutic options,
"Only offer whole-gland ablative therapy (such as cryotherapy, high-intensity focused   Strong  ultrasound, etc.) or focal ablative therapy within clinical trials or registries.",
Recommendations  Strength rating,
Watchful Waiting,
Offer WW to asymptomatic patients with life expectancy < 10 years.  Strong,
Radical prostatectomy (RP),
Radical prostatectomy can be safely delayed for at least 3 months.   Weak,
Recommendations  Strength rating,
Radical prostatectomy (RP),
Offer RP to patients with cN0 disease as part of multi-modal therapy.   Weak,
Radiotherapeutic treatment,
"Offer IMRT/VMAT plus IGRT to the prostate in combination with long-term ADT and   2 years of abiraterone to cN0M0 patients with > 2 high-risk factors (cT3-4, Gleason   > 8 or PSA > 40 ng/mL).",Strong
Offer IMRT/VMAT plus IGRT to the prostate plus pelvis in combination with    long-term ADT and 2 years of abiraterone to cN1M0 patients.,Strong
Offer patients with cN1 disease a local treatment (either RP or IMRT/VMAT plus   IGRT) plus long-term ADT.,Strong
